TTM
$3.63B
YoY change
-10.3%
5Y CAGR
+0.0%
Peak year (2021)
$8.95B
Cumulative operating income
$40.60B
Operating Income history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: $3.58B
Operating Income growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: -10.3%
Operating Income history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | $3.58B | -10.3% | −$412.80M | ||
| 2024 | $3.99B | -8.2% | −$357.90M | ||
| 2023 | $4.35B | -19.3% | −$1.04B | ||
| 2022 | $5.39B | -39.8% | −$3.56B | ||
| 2021 | $8.95B | +150.1% | +$5.37B | ||
| 2020 | $3.58B | +61.9% | +$1.37B | ||
| 2019 | $2.21B | -12.8% | −$324.60M | ||
| 2018 | $2.53B | +21.9% | +$454.81M | ||
| 2017 | $2.08B | +56.3% | +$748.85M | ||
| 2016 | $1.33B | +6.3% | +$78.83M | ||
| 2015 | $1.25B | +51.9% | +$428.00M | ||
| 2014 | $823.92M | +10.9% | +$80.87M | ||
| 2013 | $743.05M | +61.4% | +$282.54M | ||
| 2012 | $460.51M | -324.5% | +$665.67M | ||
| 2011 | −$205.16M | +110.5% | −$107.69M | ||
| 2010 | −$97.47M | +31.5% | −$23.37M | ||
| 2009 | −$74.10M | -17.5% | +$15.73M | ||
| 2008 | −$89.83M | -21.5% | +$24.62M | ||
| 2007 | −$114.45M | +6.7% | −$7.15M | ||
| 2006 | −$107.31M | -13.8% | +$17.11M | ||
| 2005 | −$124.42M | -2303.7% | −$130.07M | ||
| 2004 | $5.65M | -105.6% | +$105.63M | ||
| 2003 | −$99.99M | -18.0% | +$21.96M | ||
| 2002 | −$121.95M | +42.3% | −$36.27M | ||
| 2001 | −$85.68M | +239.0% | −$60.41M | ||
| 2000 | −$25.28M | +6.2% | −$1.48M | ||
| 1999 | −$23.80M | +90.4% | −$11.30M | ||
| 1998 | −$12.50M | +66.7% | −$5.00M | ||
| 1997 | −$7.50M | -56.6% | +$9.80M | ||
| 1996 | −$17.30M | +127.6% | −$9.70M | ||
| 1995 | −$7.60M | -74.0% | +$21.60M | ||
| 1994 | −$29.20M | -24.7% | +$9.60M | ||
| 1993 | −$38.80M | +112.0% | −$20.50M | ||
| 1992 | −$18.30M | +90.6% | −$8.70M | ||
| 1991 | −$9.60M | +190.9% | −$6.30M | ||
| 1990 | −$3.30M | — | — |
- 2025$3.58B-10.3%
- 2024$3.99B-8.2%
- 2023$4.35B-19.3%
- 2022$5.39B-39.8%
- 2021$8.95B+150.1%
- 2020$3.58B+61.9%
- 2019$2.21B-12.8%
- 2018$2.53B+21.9%
- 2017$2.08B+56.3%
- 2016$1.33B+6.3%
- 2015$1.25B+51.9%
- 2014$823.92M+10.9%
- 2013$743.05M+61.4%
- 2012$460.51M-324.5%
- 2011−$205.16M+110.5%
- 2010−$97.47M+31.5%
- 2009−$74.10M-17.5%
- 2008−$89.83M-21.5%
- 2007−$114.45M+6.7%
- 2006−$107.31M-13.8%
- 2005−$124.42M-2303.7%
- 2004$5.65M-105.6%
- 2003−$99.99M-18.0%
- 2002−$121.95M+42.3%
- 2001−$85.68M+239.0%
- 2000−$25.28M+6.2%
- 1999−$23.80M+90.4%
- 1998−$12.50M+66.7%
- 1997−$7.50M-56.6%
- 1996−$17.30M+127.6%
- 1995−$7.60M-74.0%
- 1994−$29.20M-24.7%
- 1993−$38.80M+112.0%
- 1992−$18.30M+90.6%
- 1991−$9.60M+190.9%
- 1990−$3.30M—
Operating Income values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $3.63B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual operating income for Regeneron Pharmaceuticals (REGN) came in at $3.58B – declined 10.3% year-over-year.
Regeneron Pharmaceuticals operating income has grown on net over the period, with a +0.0% compound annual growth rate over 2020–2025 (5 years).
Regeneron Pharmaceuticals operating income peaked at $8.95B in 2021; the latest annual figure is $3.58B in 2025 (60.0% below peak).
2021 marks the peak operating income at $8.95B, with the historical low of −$205.16M recorded in 2011.
Regeneron Pharmaceuticals Operating Income by Year
Regeneron Pharmaceuticals Operating Income 2025: $3.58B
2025's operating income for Regeneron Pharmaceuticals came in at $3.58B, declined 10.3% below 2024.
Regeneron Pharmaceuticals Operating Income 2024: $3.99B
Regeneron Pharmaceuticals posted operating income of $3.99B in 2024, declined 8.2% below 2023.
Regeneron Pharmaceuticals Operating Income 2023: $4.35B
In 2023, Regeneron Pharmaceuticals reported operating income of $4.35B, declined 19.3% below 2022.
Regeneron Pharmaceuticals Operating Income 2022: $5.39B
Regeneron Pharmaceuticals operating income in 2022 was $5.39B, plunged 39.8% below 2021.
Regeneron Pharmaceuticals Operating Income 2021: $8.95B
Regeneron Pharmaceuticals operating income in 2021 was $8.95B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Operating Income
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation